FW
BBIO icon

FullCircle Wealth’s BridgeBio Pharma BBIO Stock Holding History

FullCircle Wealth’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$250K Buy
+4,080
New +$199K 0.09% 226

Other funds holding BBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FullCircle Wealth's BBIO Position: Q3 2025 in Review

FullCircle Wealth opened a new position in BridgeBio Pharma (BBIO) in Q3 2025: 4,080 shares worth $250K. The stake represents 0.09% of the portfolio and ranks #226 among its holdings.

392 funds tracked by Wall St. Rank hold BBIO as of Q3 2025.

  • FullCircle Wealth held 4,080 shares of BridgeBio Pharma worth $250K as of Q3 2025.
  • BridgeBio Pharma was a new FullCircle Wealth position in Q3 2025.
  • BridgeBio Pharma made up 0.09% of FullCircle Wealth's portfolio in Q3 2025, its #226 holding.
  • 392 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2025.

Based on FullCircle Wealth's 13F filing for Q3 2025, filed 5 Nov 2025.